Distribution · Latin America · Announced 9 Nov 2026
Sandoz → Biolab
Sandoz launched Owozy, its first semaglutide, in Brazil for type 2 diabetes; the Adalvo-developed product will be commercialised by local partner Biolab & Co under a distribution and promotion agreement in a GLP-1 market of about US$2.7 billion.
Parties: Sandoz (Switzerland) → Biolab & Co (Brazil)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- Brazil
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Owozy (semaglutide)
- Announced
- 9 Nov 2026
Our analysis
Why this matters
Sandoz announced on 9 November 2026 the launch of Owozy (semaglutide 1.34 mg/mL solution for injection) in Brazil, its first semaglutide market entry. The once-weekly product, in 1.5 mL and 3.0 mL multi-dose pre-filled pens, was approved by ANVISA on 29 July 2026 for adults with insufficiently controlled type 2 diabetes, alongside diet and exercise. Owozy was developed by Adalvo and will be commercialised in Brazil by local partner Biolab & Co under a distribution and promotion agreement signed earlier in 2026.
Sandoz puts Brazil's GLP-1 market at about US$2.7 billion (IQVIA) and cites more than 16.5 million adults with diabetes in the country. It expects no material financial contribution from the launch this year. Trade press reports that Dr. Reddy's has also won ANVISA approval for semaglutide and is targeting a Brazil launch by March 2027.
The full analysis is free to read with a work email on this page.